Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- ESMO open
- Publicado em
- 7 jun 2022
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis
T Yoshino, E Van Cutsem, J Li, L Shen, T W Kim, V Sriuranpong, L Xuereb, P Aubel, R Fougeray, V Cattan et al.
Descritores MeSH
- Colonic Neoplasms
- Colorectal Neoplasms
- Frontotemporal Dementia
- Pyrrolidines
- Thymine
- Codon
- Uracil
- Randomized Controlled Trials as Topic
- Proto-Oncogene Proteins p21(ras)
- Trifluridine
Veja também
Estudos relacionados
- Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial
- Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
- Efficacy and safety of trifluridine/tipiracil (TAS-102) in patients with metastatic colorectal cancer: a systematic review and meta-analysis
- Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer